A portable brain scanner detected THC impairment more accurately than field sobriety tests

A machine learning model using portable brain imaging (fNIRS) identified THC-impaired individuals with 76.4% accuracy and only a 10% false-positive rate, outperforming standard field sobriety evaluations.

Gilman, Jodi M et al.·Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2022·Moderate EvidenceRandomized Controlled Trial
RTHC-03871Randomized Controlled TrialModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Randomized Controlled Trial
Evidence
Moderate Evidence
Sample
N=169

What This Study Found

In 169 cannabis users given oral THC or placebo in a crossover design, prefrontal cortex oxygenated hemoglobin increased after THC only in participants classified as impaired. ML models using fNIRS data achieved 76.4% accuracy and 69.8% positive predictive value with a 10% false-positive rate, compared to field sobriety exams at 67.8% accuracy, 35.4% PPV, and 35.4% false-positive rate.

Key Numbers

169 participants. fNIRS ML model: 76.4% accuracy, 69.8% PPV, 10% false positive. Field sobriety: 67.8% accuracy, 35.4% PPV, 35.4% false positive.

How They Did This

Double-blind, randomized, crossover study with 169 cannabis users aged 18-55. fNIRS measured prefrontal cortex activation before and after oral THC and placebo. Impairment defined by convergent clinical ratings and an algorithm based on heart rate and self-rated "high." Machine learning models compared to drug recognition evaluator field sobriety exams.

Why This Research Matters

There is currently no evidence-based method to detect cannabis-impaired driving. Blood THC levels do not reliably predict impairment. A portable brain-based measure could fill this critical gap.

The Bigger Picture

Unlike blood or urine tests that only detect THC presence, brain imaging captures actual functional impairment, making it more relevant for safety-critical decisions like driving.

What This Study Doesn't Tell Us

Impairment was operationalized using clinical ratings and physiological markers, not actual driving performance. Oral THC has different pharmacokinetics than inhaled. Specificity to THC versus other impairment sources not yet determined.

Questions This Raises

  • ?Would this approach work roadside in real-world conditions?
  • ?Is the neural signature specific to THC or shared with other forms of impairment?

Trust & Context

Key Stat:
76.4% accuracy with 10% false positive rate vs 35.4% for field sobriety
Evidence Grade:
Well-designed double-blind crossover trial with large sample, though impairment definition was proxy-based, not driving-performance based.
Study Age:
Published in 2022.
Original Title:
Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging.
Published In:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 47(4), 944-952 (2022)
Database ID:
RTHC-03871

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled TrialGold standard for testing treatments
This study
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Participants are randomly assigned to treatment or placebo groups to test cause and effect.

What do these levels mean? →

Frequently Asked Questions

How does fNIRS detect impairment?

fNIRS measures blood oxygenation changes in the prefrontal cortex using light. After THC, impaired individuals showed distinct activation patterns and connectivity changes that machine learning models could identify.

Is this ready for roadside use?

Not yet. The technology is portable and the results are promising, but further work is needed to confirm specificity to THC impairment and validate the approach in real-world roadside conditions.

Read More on RethinkTHC

Cite This Study

RTHC-03871·https://rethinkthc.com/research/RTHC-03871

APA

Gilman, Jodi M; Schmitt, William A; Potter, Kevin; Kendzior, Brian; Pachas, Gladys N; Hickey, Sarah; Makary, Meena; Huestis, Marilyn A; Evins, A Eden. (2022). Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 47(4), 944-952. https://doi.org/10.1038/s41386-021-01259-0

MLA

Gilman, Jodi M, et al. "Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging.." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. https://doi.org/10.1038/s41386-021-01259-0

RethinkTHC

RethinkTHC Research Database. "Identification of ∆9-tetrahydrocannabinol (THC) impairment u..." RTHC-03871. Retrieved from https://rethinkthc.com/research/gilman-2022-identification-of-9tetrahydrocannabinol-thc

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.